Yi Que

891 total citations
51 papers, 595 citations indexed

About

Yi Que is a scholar working on Oncology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yi Que has authored 51 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 18 papers in Neurology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yi Que's work include Neuroblastoma Research and Treatments (16 papers), Sarcoma Diagnosis and Treatment (16 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Yi Que is often cited by papers focused on Neuroblastoma Research and Treatments (16 papers), Sarcoma Diagnosis and Treatment (16 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Yi Que collaborates with scholars based in China and United States. Yi Que's co-authors include Xing Zhang, Yao Liang, Wei Xiao, Yizhuo Zhang, Yuanxiang Guan, Wei Xiao, Yongming Chen, Zhiwei Zhou, Yuanfang Li and Haibo Qiu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yi Que

47 papers receiving 588 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yi Que China 14 347 208 193 139 84 51 595
Emilie Lavergne France 14 266 0.8× 157 0.8× 191 1.0× 218 1.6× 50 0.6× 23 617
M.T. Allende Spain 13 165 0.5× 150 0.7× 184 1.0× 99 0.7× 81 1.0× 25 589
Kyung Han Nam South Korea 14 428 1.2× 346 1.7× 227 1.2× 99 0.7× 154 1.8× 46 832
Shinji Fujii Japan 15 356 1.0× 210 1.0× 205 1.1× 100 0.7× 54 0.6× 41 676
Ji Hyun Lee South Korea 12 269 0.8× 232 1.1× 282 1.5× 71 0.5× 80 1.0× 23 609
Isabelle Laure Ray-Coquard France 15 625 1.8× 235 1.1× 155 0.8× 86 0.6× 55 0.7× 110 852
Prasanna Kumar United States 12 244 0.7× 94 0.5× 186 1.0× 152 1.1× 55 0.7× 42 582
Phillip Barnette United States 11 255 0.7× 146 0.7× 189 1.0× 47 0.3× 71 0.8× 26 672
Ji Zhou China 16 292 0.8× 174 0.8× 129 0.7× 31 0.2× 91 1.1× 39 621
Francesca Franzi Italy 12 410 1.2× 152 0.7× 101 0.5× 157 1.1× 106 1.3× 23 700

Countries citing papers authored by Yi Que

Since Specialization
Citations

This map shows the geographic impact of Yi Que's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Que with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Que more than expected).

Fields of papers citing papers by Yi Que

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Que. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Que. The network helps show where Yi Que may publish in the future.

Co-authorship network of co-authors of Yi Que

This figure shows the co-authorship network connecting the top 25 collaborators of Yi Que. A scholar is included among the top collaborators of Yi Que based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi Que. Yi Que is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lü, Suying, Yi Que, Dongyang Liu, et al.. (2025). Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. EClinicalMedicine. 84. 103258–103258. 1 indexed citations
2.
Que, Yi, et al.. (2024). Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1‐Dependent Regulation of MAD2L1 mRNA Stability. Advanced Science. 11(44). e2405611–e2405611. 2 indexed citations
3.
Xiao, Wei, Liping Xu, Jinghua Wang, et al.. (2024). FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Therapy. 31(10). 1571–1584. 14 indexed citations
4.
Li, Mengzhen, Yi Wang, Yu Zhang, et al.. (2024). MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma. Cell Death and Disease. 15(2). 124–124. 7 indexed citations
5.
Que, Yi, Juan Wang, Feifei Sun, et al.. (2023). Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduction and Targeted Therapy. 8(1). 392–392. 5 indexed citations
6.
Li, Mengzhen, Yang Hu, Yanjie Xu, et al.. (2023). The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma. International Journal of Oncology. 64(2). 8 indexed citations
7.
Hong, Dong‐Chun, Jing Yang, Cong Sun, et al.. (2023). Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade. Clinical Cancer Research. 29(15). 2869–2884. 7 indexed citations
8.
Liu, Mengmeng, et al.. (2022). Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma. Clinical & Experimental Immunology. 209(2). 127–139. 9 indexed citations
9.
Lü, Suying, Huimou Chen, Liu-Hong Wu, et al.. (2022). The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors. Frontiers in Pharmacology. 13. 711704–711704. 4 indexed citations
10.
Liu, Mengmeng, et al.. (2022). A Pan-Cancer Analysis of IRAK1 Expression and Their Association With Immunotherapy Response. Frontiers in Molecular Biosciences. 9. 904959–904959. 10 indexed citations
11.
Chen, Binbin, Huimou Chen, Suying Lü, et al.. (2022). KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis. Cell Death and Disease. 13(4). 354–354. 22 indexed citations
12.
Que, Yi, Xiao-Long Zhang, Zexian Liu, et al.. (2021). Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. Journal for ImmunoTherapy of Cancer. 9(2). e001696–e001696. 67 indexed citations
13.
Wang, Juan, Lian Zhang, Yi Que, et al.. (2021). Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor. Frontiers in Oncology. 11. 721564–721564. 4 indexed citations
14.
Que, Yi, Yang Hu, Dong‐Chun Hong, & Yizhuo Zhang. (2021). Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov. Journal for ImmunoTherapy of Cancer. 9(9). e002920–e002920. 11 indexed citations
15.
Zhu, Xiaoqin, Jia Zhu, Feifei Sun, et al.. (2021). Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen. Pharmacogenomics and Personalized Medicine. Volume 14. 369–377. 3 indexed citations
16.
Que, Yi, et al.. (2019). LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. Cancer Biology and Medicine. 16(2). 331–331. 45 indexed citations
17.
Que, Yi, et al.. (2019). ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma. Oncogene. 39(1). 151–163. 14 indexed citations
18.
Liang, Yao, Wei Wang, Yi Que, et al.. (2018). Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma. BMC Cancer. 18(1). 942–942. 35 indexed citations
19.
Wang, Yao, et al.. (2017). The prognostic value of preoperative serum HDL cholesterol in patients with resectable acral melanoma. 10(3). 5134–5142. 1 indexed citations
20.
Delodder, Frederik, Lucas Liaudet, Yi Que, et al.. (2010). Pancreatic stone protein (PSP): a biomarker of sepsis. IRIS. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emilie Lavergne Breakdown of academic impact, for papers by M.T. Allende Breakdown of academic impact, for papers by Kyung Han Nam Breakdown of academic impact, for papers by Shinji Fujii Breakdown of academic impact, for papers by Ji Hyun Lee Breakdown of academic impact, for papers by Isabelle Laure Ray-Coquard Breakdown of academic impact, for papers by Prasanna Kumar Breakdown of academic impact, for papers by Phillip Barnette Breakdown of academic impact, for papers by Ji Zhou Breakdown of academic impact, for papers by Francesca Franzi
Rankless by CCL
2026